CME/ABO CC Part II Webinar

To register, click on the date & time that best fits your schedule. Please note, each session will contain the same presentations and therefore CME credit can only be provided once.

---

Tuesday, June 28, 2022 | 7:00 – 8:15 pm ET
Wednesday, June 29, 2022 | 8:00 – 9:15 pm ET
Wednesday, July 20, 2022 | 12:00 – 1:15 pm ET
Thursday, July 21, 2022 | 7:00 – 8:15 pm ET

Topics

• Eye on Surgical Delivery Systems Extend Treatment Intervals in nAMD and DME
• Surgical Tips and Techniques: PDS and RGX–314 Step by Step
• Avoiding Complications With RGX–314 and PDS
• PDS in the Office – How to Refill
• LIVE Question & Answer

Overview

Intravitreal anti-vascular endothelial growth factor (VEGF) based treatment protocols for the management of retinal vascular diseases has provided significant visual and anatomical improvements, but treatment burden and loss of patient adherence due to dosing schedules often result in suboptimal outcomes. To address these unmet needs, unique delivery systems have been developed that reduce the need for frequent dosing of therapy beyond those utilized in current treatment protocols. Ongoing clinical studies are evaluating gene therapy to reduce treatment burden, while the FDA-approved Port Delivery System (PDS) with ranibizumab has demonstrated maintenance of visual acuity gains with extended treatment intervals out to 6 months. To achieve optimal efficacy and safety outcomes with these new extended treatment modalities, at the initiation of their use, unique surgical approaches must be utilized. In this CME activity, experts in the field will discuss how novel surgical advances can enhance outcomes while reducing treatment burden, review key procedural steps and surgical techniques pertaining to their use, and evaluate processes and procedures that can reduce complications from surgeries to optimize outcomes in patients with retinal vascular diseases.

Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with retinal vascular diseases.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Recognize how novel surgical advances can enhance outcomes in patients with retinal vascular diseases by reducing treatment burden.
• Describe key procedural steps and surgical techniques pertaining to the use of the PDS with ranibizumab and the gene therapy RGX-314 that can improve outcomes in patients with retinal vascular diseases.
• Examine techniques that can be used in the office for refilling and exchange of the PDS with ranibizumab.
• Evaluate processes and procedures that can reduce complications from surgeries that include the use of the PDS with ranibizumab or the RGX-314 gene therapy for retinal vascular diseases.

Activity Chair

Arshad M. Khanani, MD, MA

Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV

Faculty

John W. Kitchens, MD

Vitreoretinal Surgeon
Retina Associates of Kentucky
Lexington, KY

Dante J. Pieramici, MD

Director, California Retina Research Foundation
Partner, California Retina Consultants
Santa Barbara, CA

---

Contact Us

Vindico Medical Education
6900 Grove Road
Thorofare, NJ 08086

Email Us

This continuing education activity is provided by

This activity is supported by an educational grant from Genentech, a member of the Roche Group.